Basilea’s isavuconazole obtains FDA orphan drug status
Isavuconazole is being investigated in phase 3 studies for the treatment of severe invasive fungal infections. Basilea chief medical officer Prof. Achim Kaufhold said invasive aspergillosis affects patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.